Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 5/20 | 0.49 |
| ▸ | RAMP3 | O60896 | 9/20 | 0.42 |
| ▸ | CALCR | P30988 | 9/20 | 0.42 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.41 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25527056 | 1.00 | APLNR (0.49) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL22018314 | 0.99 | APLNR (0.48) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL22018340 | 0.99 | APLNR (0.48) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL22018363 | 0.99 | APLNR (0.48) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL22018502 | 0.99 | APLNR (0.48) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL22018380 | 0.99 | APLNR (0.48) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL22018809 | 0.99 | APLNR (0.48) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL22018370 | 0.99 | APLNR (0.48) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL22018810 | 0.99 | APLNR (0.48) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL29308439 | 0.99 | APLNR (0.48) | APLNRRAMP3CALCRNMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146455-A1 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | YUYU PHARMA, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146455-A1 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | VIP, TSLP, IAPP | APLNR 90/4885RAMP3 1263/4885CALCR 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.